GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK has announced the purchase of 170,000 of its own ordinary shares as part of its ...

A strong performer already, GSK stock is trading up 44% in 2025, yet its stock remains a good bargain. GSK trades for a ...

GSK (LSE:GSK) shares have edged slightly lower as investors digest recent trading activity and look for new signals on the company’s next move. Over the past month, the stock has delivered a 12% gain, ...

GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term ...

Investing.com -- AnaptysBio Inc (NASDAQ:ANAB) stock dropped 11.1% in premarket trading Friday after the clinical-stage biotechnology company announced it has filed a lawsuit against TESARO, Inc., a ...

Anaptys alleges that Tesaro violated the terms of the 2014 deal between the two companies. ・The company said that it ...

Investing.com -- Bank of America (BofA) has turned more constructive on two of Europe’s largest drugmakers, upgrading ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio.